Gastroenterology, Hepatology and Nutrition
3020 Children's Way
San Diego, CA 92123
Gastroenterology, Hepatology and Nutrition
Rady Children's Specialists of San Diego
Rady Children's Specialists
Universidad de Buenos Aires
Pediatric Gastroenterology, Pediatrics
Dr. Ariel Feldstein is chief of the Gastroenterology, Hepatology & Nutrition Division at Rady Children's Hospital-San Diego and a professor of pediatrics at UC San Diego School of Medicine.
After graduating from the Universidad de Buenos Aires Medical School and completing a postdoctoratal program in physiology at the Mayo Clinic, Dr. Feldstein went on to become the director of research for the Pediatric Institute at the Cleveland Clinic before moving to San Diego in 2011.
Dr. Feldstein oversees one of the largest pediatric gastroenterology divisions in the country, which is a top-ranked program by US News & World Report. He is a renowned pediatric hepatologist who pioneered the development of non-invasive blood tests to monitor liver damage. His research is supported by several grants from the National Institutes of Health, professional associations such as the American College of Gastroenterology and pharmaceutical industry leaders. He and his lab have made significant contributions to understanding and developing therapies for obesity-associated liver disease, now the most common form of chronic liver disease in children.
Dr. Feldstein has published over 120 peer-reviewed publications in various medical journals. He currently serves as the associate editor of Seminars for Liver Disease and has held editorial positions on other gastroenterology and hepatology journals. He is a member of the Society for Pediatric Research and numerous specialty societies and has held leadership roles in the American Gastroenterological Association and the American Association for the Study of Liver Diseases.
His goal is to use his research to develop safe and effective diagnostic and therapeutic strategies for patients with highly prevalent and potentially serious conditions.
Liver Bid-suppression for treatment of fibrosis associated with nonalcoholic steatohepatitis.
Eguchi A, De Mollerat Du Jeu X, Johnson CD, Nektaria A, Feldstein AE
Role of the TM6SF2 rs58542926 in the pathogenesis of non-alcoholic pediatric fatty liver disease (NAFLD): A multiethnic study.
Goffredo M, Caprio S, Feldstein AE, D'Adamo E, Shaw MM, Pierpont B, Savoye M, Zhao H, Bale AE, Santoro N
Etiology, outcome and prognostic factors of childhood acute liver failure in a German Single Center.
Kathemann S, Bechmann LP, Sowa JP, Manka P, DechÃªne A, Gerner P, Lainka E, Hoyer PF, Feldstein AE, Canbay A
Burden of nonalcoholic fatty liver disease and advanced fibrosis in a Texas Hispanic community cohort.
Pan JJ, Fisher-Hoch SP, Chen C, Feldstein AE, McCormick JB, Rahbar MH, Beretta L, Fallon MB
Redox nanoparticles as a novel treatment approach for inflammation and fibrosis associated with nonalcoholic steatohepatitis.
Eguchi A, Yoshitomi T, Lazic M, Johnson CD, Vong LB, Wree A, Povero D, Papouchado BG, Nagasaki Y, Feldstein AE
Serum cytokeratin-18 fragment levels predict development of type 2 diabetes mellitus in adult patients with NAFLD.
Nagpal SJ, Lopez R, Feldstein AE, Alkhouri N
Hepatocyte-specific Bid depletion reduces tumor development by suppressing inflammation-related compensatory proliferation.
Wree A, Johnson CD, Font-Burgada J, Eguchi A, Povero D, Karin M, Feldstein AE
Microparticles release by adipocytes act as "find-me" signals to promote macrophage migration.
Eguchi A, Mulya A, Lazic M, Radhakrishnan D, Berk MP, Povero D, Gornicka A, Feldstein AE
Circulating Soluble Fas and Fas Ligand Levels Are Elevated in Children with Nonalcoholic Steatohepatitis.
Alkhouri N, Alisi A, Okwu V, Matloob A, Ferrari F, Crudele A, De Vito R, Lopez R, Feldstein AE, Nobili V
Beneficial effects of mineralocorticoid receptor blockade in experimental non-alcoholic steatohepatitis.
Pizarro M, SolÃs N, Quintero P, Barrera F, Cabrera D, Rojas-de Santiago P, Arab JP, Padilla O, Roa JC, Moshage H, Wree A, Inzaugarat E, Feldstein AE, Fardella CE, Baudrand R, Riquelme A, Arrese M
Circulating microRNAs: emerging biomarkers of liver disease.
Arrese M, Eguchi A, Feldstein AE
Endoscopic treatment of pediatric post-transplant biliary complications is safe and effective.
DechÃªne A, Kodde C, Kathemann S, Treckmann J, Lainka E, Paul A, Gerken G, Feldstein AE, Hoyer PF, Canbay A
The evaluation of hepatic fibrosis scores in children with nonalcoholic fatty liver disease.
Mansoor S, Yerian L, Kohli R, Xanthakos S, Angulo P, Ling S, Lopez R, Christine CK, Feldstein AE, Alkhouri N
Circulating extracellular vesicles with specific proteome and liver microRNAs are potential biomarkers for liver injury in experimental fatty liver disease.
Povero D, Eguchi A, Li H, Johnson CD, Papouchado BG, Wree A, Messer K, Feldstein AE
Transient receptor potential vanilloid 1 gene deficiency ameliorates hepatic injury in a mouse model of chronic binge alcohol-induced alcoholic liver disease.
Liu H, Beier JI, Arteel GE, Ramsden CE, Feldstein AE, McClain CJ, Kirpich IA
Adipocyte cell size, free fatty acids and apolipoproteins are associated with non-alcoholic liver injury progression in severely obese patients.
Wree A, Schlattjan M, Bechmann LP, Claudel T, Sowa JP, Stojakovic T, Scharnagl H, KÃ¶feler H, Baba HA, Gerken G, Feldstein AE, Trauner M, Canbay A
Reduced dietary omega-6 to omega-3 fatty acid ratio and 12/15-lipoxygenase deficiency are protective against chronic high fat diet-induced steatohepatitis.
Lazic M, Inzaugarat ME, Povero D, Zhao IC, Chen M, Nalbandian M, Miller YI, CherÃ±avsky AC, Feldstein AE, Sears DD
Arginase 2 deficiency results in spontaneous steatohepatitis: a novel link between innate immune activation and hepatic de novo lipogenesis.
Navarro LA, Wree A, Povero D, Berk MP, Eguchi A, Ghosh S, Papouchado BG, Erzurum SC, Feldstein AE
Adipocyte cell death, fatty liver disease and associated metabolic disorders.
Eguchi A, Feldstein AE
Leptin deficiency recapitulates the histological features of pulmonary arterial hypertension in mice.
Aytekin M, Tonelli AR, Farver CF, Feldstein AE, Dweik RA
NLRP3 inflammasome activation is required for fibrosis development in NAFLD.
Wree A, McGeough MD, PeÃ±a CA, Schlattjan M, Li H, Inzaugarat ME, Messer K, Canbay A, Hoffman HM, Feldstein AE
Caspase 3 inactivation protects against hepatic cell death and ameliorates fibrogenesis in a diet-induced NASH model.
Thapaliya S, Wree A, Povero D, Inzaugarat ME, Berk M, Dixon L, Papouchado BG, Feldstein AE
Lipidomic profiling of bile in distinguishing benign from malignant biliary strictures: a single-blinded pilot study.
Navaneethan U, Gutierrez NG, Venkatesh PG, Jegadeesan R, Zhang R, Jang S, Sanaka MR, Vargo JJ, Parsi MA, Feldstein AE, Stevens T
Letter: gender-associated cell-free microRNA profiles in non-alcoholic fatty liver disease--authors' reply.
Newton KP, Awai HI, Feldstein AE, Schwimmer JB
Differential regulation of inflammation and apoptosis in Fas-resistant hepatocyte-specific Bid-deficient mice.
Lazic M, Eguchi A, Berk MP, Povero D, Papouchado B, Mulya A, Johnson CD, Feldstein AE
See the full listing of this physician's publications on PubMed, a service of the National Library of Medicine.
PubMed is a third-party website and not affiliated with Rady Children's Hospital-San Diego.